Real-world therapeutic performance of pirfenidone for connective tissue disease-associated interstitial lung diseases
Therapeutic Advances in Respiratory Disease · 2024-11 · 18
DOI: 10.1177/17534666241292507 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 08.11.2024. Verfasst von Xueting Yuan und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Hauptthemen laut MEDLINE: Pyridones, Lung Diseases, Interstitial, Connective Tissue Diseases, Lung. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CAMS Innovation Fund for Medical Sciences, National High Level Hospital Clinical Research Funding, The Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences.
Abstract (Originalsprache)
Background
Pirfenidone (PFD) is commonly applied for antifibrotic treatment in patients with idiopathic pulmonary fibrosis but has rarely been studied in cases with connective tissue disease-associated interstitial lung diseases (CTD-ILDs).
Objectives
We aimed to examine the efficacy of PFD in patients with CTD-ILD based on real-world data.
Design
A retrospective cohort study.
Methods
This study assessed the clinical features of CTD-ILD patients with or without a 6-month PFD treatment. A linear mixed effects model was employed to evaluate the effectiveness of PFD in alleviating lung function changes. Differences in response to PFD were analyzed based on CTD subtype, imaging classification, and pattern of pulmonary function at baseline.
Results
A total of 289 patients with CTD-ILD were included, with 155 (53.6%) receiving PFD treatment and the remaining constituting the control group. Patients with the usual interstitial pneumonia (UIP) pattern were more likely to receive PFD treatment, and a relatively lower proportion of cases in the PFD group received immunosuppressive therapies compared to the control group ( p < 0.05). At the 6-month follow-up, patients in the PFD group demonstrated a more significant improvement in forced vital capacity (FVC) and diffusion capacity for carbon monoxide (DLCO) (ΔFVC%: 2.9% vs 0.45%, p = 0.009; ΔDLCO%: 1.9% vs −1.1%, p = 0.004). In the linear mixed model analysis, there was a statistically significant group-time interaction between FVC% and DLCO% changes over time (FVC%: β = 4.52, p < 0.001; DLCO%: β = 4.13, p = 0.003). Furthermore, subgroup analysis indicated that pirfenidone may have superior therapeutic effects in patients with systemic sclerosis (SSc)-associated ILD, non-UIP pattern, and restrictive pattern of lung function at baseline.
Conclusion
This study provided real-world data demonstrating the effectiveness of PFD in terms of lung function improvement in patients with CTD-ILD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China.
- Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Beijing, China.
- Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.
- Department of Rheumatology and Immunology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Rheumatology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
ORCID-Profile: Qian Wang
Förderung
- CAMS Innovation Fund for Medical Sciences
- National High Level Hospital Clinical Research Funding
- The Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
- Chinese National Key Technology R&D Program, Ministry of Science and Technology
Zitieren
APA
Yuan, X., Yu, C., Liu, S., Shu, Q., Duan, X., Tang, L., Peng, L., Zhou, S., Wu, C., Zhao, J., Xu, D., Song, L., Huang, H., Li, M., Wang, Y., Wang, Q., & Zeng, X. (2024). Real-world therapeutic performance of pirfenidone for connective tissue disease-associated interstitial lung diseases. Therapeutic Advances in Respiratory Disease, 18. https://doi.org/10.1177/17534666241292507
Vancouver
Yuan X, Yu C, Liu S, Shu Q, Duan X, Tang L, et al. Real-world therapeutic performance of pirfenidone for connective tissue disease-associated interstitial lung diseases. Therapeutic Advances in Respiratory Disease. 2024;18. doi:10.1177/17534666241292507
BibTeX
@article{Yuan2024,
author = {Yuan, Xueting and Yu, Chen and Liu, Shengyun and Shu, Qiang and Duan, Xinwang and Tang, Lin and Peng, Liying and Zhou, Shuang and Wu, Chanyuan and Zhao, Jiuliang and Xu, Dong and Song, Lan and Huang, Hui and Li, Mengtao and Wang, Yanhong and Wang, Qian and Zeng, Xiaofeng},
title = {Real-world therapeutic performance of pirfenidone for connective tissue disease-associated interstitial lung diseases},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2024},
volume = {18},
doi = {10.1177/17534666241292507}
}
EUVIMED